Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma
暂无分享,去创建一个
G. Morgan | W. Gregory | M. Drayson | M. Jenner | F. Davies | G. Cook | G. Jackson | D. Cairns | M. Kaiser | R. Owen | C. Pawlyn | Zoe Craig | A. Hockaday | C. Bygrave | Z. Craig | G. Jackson
[1] G. Morgan,et al. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Haematology.
[2] H. Goldschmidt,et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. , 2019, Blood.
[3] G. Morgan,et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.
[4] G. Morgan,et al. Subclonal TP53 copy number is associated with prognosis in multiple myeloma. , 2018, Blood.
[5] C. Messiou,et al. Whole-Body Imaging in Multiple Myeloma. , 2018, Magnetic resonance imaging clinics of North America.
[6] M. Kumar,et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. , 2018, Blood.
[7] G. Morgan,et al. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients , 2017, Leukemia.
[8] N. Munshi,et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.
[9] A. Órfão,et al. New criteria for response assessment: role of minimal residual disease in multiple myeloma. , 2015, Blood.